Show simple item record

dc.contributor.authorKlimek, L
dc.contributor.authorBerger, WE
dc.contributor.authorBousquet, J
dc.contributor.authorKeith, PK
dc.contributor.authorSmith, P
dc.contributor.authorSole, D
dc.contributor.authorScadding, G
dc.contributor.authorKuhl, HC
dc.contributor.authorNguyen, DT
dc.contributor.authorKopietz, F
dc.contributor.authorKoltun, A
dc.date.accessioned2021-12-16T05:24:26Z
dc.date.available2021-12-16T05:24:26Z
dc.date.issued2021
dc.identifier.issn1018-2438en_US
dc.identifier.doi10.1159/000516417en_US
dc.identifier.urihttp://hdl.handle.net/10072/410951
dc.description.abstractAllergic rhinitis (AR) is prevalent, and many patients present with moderate-to-severe symptomatic disease. The majority of patients are not satisfied with their AR treatment, despite the use of concurrent medications. These gaps underscore the need for treatment with more effective options for moderate-to-severe AR. The authors' objective was to review systematically the efficacy and safety of MP-AzeFlu for the treatment of AR. The primary outcomes studied were nasal, ocular, and total symptoms. Other outcomes included time to onset and of AR control, quality of life, and safety. Searches of PubMed and Cochrane databases were conducted on May 14, 2020, with no date restrictions, to identify publications reporting data on MP-AzeFlu. Clinical studies of any phase were included. Studies were excluded if they were not in English, were review articles, did not discuss the safety and efficacy of MP-AzeFlu for AR symptoms. Treatment of AR with MP-AzeFlu results in effective, sustained relief of nasal and ocular symptoms, and faster onset and time to control compared with intranasal azelastine or fluticasone propionate. Long-term use of MP-AzeFlu was safe, with benefits in children, adults, and adults aged ≥65 years. Other treatment options, including fluticasone propionate and azelastine alone or the combination of intranasal corticosteroids and oral antihistamine, do not provide the same level of efficacy as MP-AzeFlu in terms of rapid and sustained relief of the entire AR symptom complex. Furthermore, MP-AzeFlu significantly improves patient quality of life. MP-AzeFlu is a currently available combination that may satisfy all these patient needs and expectations.en_US
dc.description.peerreviewedYesen_US
dc.languageengen_US
dc.publisherS. Karger AGen_US
dc.relation.ispartofpagefrom1026en_US
dc.relation.ispartofpageto1035en_US
dc.relation.ispartofissue11en_US
dc.relation.ispartofjournalInternational Archives of Allergy and Immunologyen_US
dc.relation.ispartofvolume182en_US
dc.subject.fieldofresearchImmunologyen_US
dc.subject.fieldofresearchcode3204en_US
dc.subject.keywordsAllergic rhinitisen_US
dc.subject.keywordsAzelastineen_US
dc.subject.keywordsFluticasone propionateen_US
dc.subject.keywordsMP-AzeFluen_US
dc.subject.keywordsNasal symptomsen_US
dc.titleMP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Reviewen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationKlimek, L; Berger, WE; Bousquet, J; Keith, PK; Smith, P; Sole, D; Scadding, G; Kuhl, HC; Nguyen, DT; Kopietz, F; Koltun, A, MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review, International Archives of Allergy and Immunology, 2021, 182 (11), pp. 1026-1035en_US
dcterms.dateAccepted2021-04-07
dc.date.updated2021-12-01T01:53:43Z
gro.hasfulltextNo Full Text
gro.griffith.authorSmith, Peter K.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record